Vertex Pharmaceuticals’ Phase II hepatitis C protease inhibitor VX-950 has been licensed by Janssen Pharmaceutica in selected territories with Tibotec Pharmaceuticals commercializing VX-950. This alliance shoots Vertex’s share price to 14.6% and also endorses the claims that VX-950 has blockbuster potential. With the drop in attrition rate for the product VX-950, is in a good position and has an edge both in timing and efficacy and a blockbuster market waiting as well.